ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Entera Bio reported first comparative Phase 1 PK/PD results for its oral peptide EB613 at ENDO 2026. In a 15-person study, single-tablet EB613 showed comparable exposure and calcemic effects to multi-tablet EB613 and Forteo, with similar PTH suppression and no drug-related serious AEs. Entera plans a Phase 3 single daily tablet trial.
EB613’s single-tablet PK/PD comparability to Forteo and multi-tablet EB613 de-risks the dosing simplification for the upcoming Phase 3.
Entera reported Phase 1 comparative PK/PD data showing single-tablet EB613 is comparable to multi-tablet EB613 and Forteo, supporting a planned Phase 3.
Potential near-term positive bias as traders price improved probability of Phase 3 execution and patient adoption versus injection-based anabolic therapy.
Background
EB613 is Entera’s oral PTH(1-34) tablet program intended to deliver anabolic osteoporosis treatment without injections; Forteo is the injectable comparator.
Why it matters
The new comparative Phase 1 oral presentation supports selecting a single daily tablet regimen for the planned Phase 3, potentially improving commercial adoption and reducing regimen complexity risk.
Market relevance
Traders get a concrete clinical de-risking datapoint (single-tablet PK/PD comparability) tied to a specific next step (planned Phase 3).
Market effects
Reinforces the oral-peptide/peptide-tablet platform thesis in osteoporosis and may increase investor attention on oral anabolic approaches versus injection incumbents.
Limited direct regional impact; primarily US-listed biotech sentiment.
Osteoporosis is global; improved oral dosing convenience could broaden market potential if Phase 3 confirms efficacy/safety.
Alternative perspectives
Phase 1 PK/PD comparability does not guarantee Phase 3 efficacy or long-term safety; investors may overreact to dosing-formulation progress.
The text emphasizes biomarker/calcemic effects and preference data, but provides no Phase 3 efficacy outcomes or detailed safety signals beyond “no serious adverse events,” leaving key risk unaddressed.
Key entities
- companyEntera Bio Ltd.
Clinical-stage oral peptide company developing EB613 for osteoporosis; reported comparative Phase 1 PK/PD data at ENDO 2026.
- drug_programEB613
Oral PTH(1-34) tablet candidate; single-tablet regimen showed PK/PD comparability to multi-tablet EB613 and Forteo in Phase 1.
- comparatorForteo
Teriparatide subcutaneous injection (Eli Lilly) used as the PK/PD comparator in Entera’s Phase 1 study.
- conferenceENDO 2026
Endocrine Society annual meeting where the late-breaking oral presentation was delivered.
